Department of Imaging, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Nanotheranostics. 2022 Jan 1;6(1):31-49. doi: 10.7150/ntno.62970. eCollection 2022.
In the last two decades, the application of surface enhanced Raman scattering (SERS) nanoparticles for preclinical cancer imaging has attracted increasing attention. Raman imaging with SERS nanoparticles offers unparalleled sensitivity, providing a platform for molecular targeting, and granting multiplexed and multimodal imaging capabilities. Recent progress has been facilitated not only by the optimization of the SERS contrast agents themselves, but also by the developments in Raman imaging approaches and instrumentation. In this article, we review the principles of Raman scattering and SERS, present advances in Raman instrumentation specific to cancer imaging, and discuss the biological means of ensuring selective uptake of SERS contrast agents for targeted, multiplexed, and multimodal imaging applications. We offer our perspective on areas that must be addressed in order to facilitate the clinical translation of SERS contrast agents for imaging in oncology.
在过去的二十年中,表面增强拉曼散射(SERS)纳米粒子在临床前癌症成像中的应用引起了越来越多的关注。SERS 纳米粒子的 Raman 成像提供了无与伦比的灵敏度,为分子靶向提供了平台,并具有多重和多模式成像的能力。最近的进展不仅得益于 SERS 造影剂本身的优化,还得益于 Raman 成像方法和仪器的发展。在本文中,我们回顾了 Raman 散射和 SERS 的原理,介绍了专门用于癌症成像的 Raman 仪器的进展,并讨论了确保 SERS 造影剂选择性摄取的生物学手段,以实现靶向、多重和多模式成像应用。我们提供了我们对必须解决的领域的看法,以便促进 SERS 造影剂在肿瘤学成像中的临床转化。